Allergic Bronchopulmonary Aspergillosis

  • Christian M. Sebat
  • Mark V. Avdalovic
  • Brian M. Morrissey


Allergic bronchopulmonary aspergillosis (ABPA) describes a syndrome in which patients with asthma harbor the saprophytic growth of Aspergillus species within their airways. An intense allergic inflammation results in response to fungal antigens leading to clinical disease. Recurring clinical exacerbations can lead to bronchiectasis, pulmonary fibrosis and even death. ABPA is present in 1–2% of all asthmatics and up to 15% of patients with cystic fibrosis (CF) (1). While the initial manifestations of disease may be subtle, more severe disease may be dramatic and, at times, life-threatening. ABPA may go unrecognized, since the early clinical course may be as indolent as a moderate to severe persistent asthma. As with rhinosinusitis, gastroesophageal reflux disease (GERD) and COPD, ABPA should be included whenever considering an asthma diagnosis. Assiduous therapy in ABPA can decrease the frequency of exacerbations and may slow the progressive lung damage, leading to pulmonary fibrosis and death.


Cystic Fibrosis Cystic Fibrosis Patient Invasive Fungal Disease Eosinophilic Pneumonia Invasive Fungal Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Geller D. E., H. Kaplowitz, M. J. Light, A. A. Colin. Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis. Reported Prevalence, Regional Distribution, and Patient Characteristics. Chest. Vol 116 no. 3 639–646, 1999.PubMedCrossRefGoogle Scholar
  2. 2.
    Aron, Y., T. Bienvenu, D. Hubert, D. Dusser, J. Dall’Ava, and B. S. Polla: HLA-DR polymorphism in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 104(4 Pt 1):891–2, 1999.Google Scholar
  3. 3.
    Mastella, G., M. Rainisio, H. K. Harms, M. E. Hodson, C. Koch, J. Navarro, B. Strandvik, and S. G. McKenzie: Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis. Eur Respir J. 16(3):464–71, 2000.PubMedCrossRefGoogle Scholar
  4. 4.
    Hinson, K. F., A. J. Moon, and N. S. Plummer: Broncho-pulmonary aspergillosis; a review and a report of eight new cases. Thorax. 7(4):317–33, 1952.PubMedCrossRefGoogle Scholar
  5. 5.
    Wark, P. A., N. Saltos, J. Simpson, S. Slater, M. J. Hensley, and P. G. Gibson: Induced sputum eosinophils and neutrophils and bronchiectasis severity in allergic bronchopulmonary aspergillosis. Eur Respir J. 16(6):1095–101, 2000.PubMedCrossRefGoogle Scholar
  6. 6.
    Skov, M., L. K. Poulsen, and C. Koch: Increased antigen-specific Th-2 response in allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis. Pediatr Pulmonol. 27(2):74–9, 1999.PubMedCrossRefGoogle Scholar
  7. 7.
    Grunig, G., D. B. Corry, M. W. Leach, B. W. Seymour, V. P. Kurup, and D. M. Rennick: Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis. J Exp Med. 185(6):1089–99, 1997.PubMedCrossRefGoogle Scholar
  8. 8.
    Kheradmand, F., A. Kiss, J. Xu, S. H. Lee, P. E. Kolattukudy, and D. B. Corry: A protease-activated pathway underlying Th cell type 2 activation and allergic lung disease. J Immunol. 169(10):5904–11, 2002.PubMedGoogle Scholar
  9. 9.
    Khan, S., J. S. McClellan, and A. P. Knutsen: Increased sensitivity to IL-4 in patients with allergic bronchopulmonary aspergillosis. Int Arch Allergy Immunol. 123(4):319–26, 2000.PubMedCrossRefGoogle Scholar
  10. 10.
    Stevens, D. A., V. L. Kan, M. A. Judson, V. A. Morrison, S. Dummer, D. W. Denning, J. E. Bennett, T. J. Walsh, T. F. Patterson, and G. A. Pankey: Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis. 30(4):696–709, 2000.PubMedCrossRefGoogle Scholar
  11. 11.
    Chung, Y., J. R. Kraut, A. M. Stone, and J. Valaitis: Disseminated aspergillosis in a patient with cystic fibrosis and allergic bronchopulmonary aspergillosis. Pediatr Pulmonol. 17(2):131–4, 1994.PubMedCrossRefGoogle Scholar
  12. 12.
    Bodey, G. P., and A. S. Glann: Central nervous system aspergillosis following steroidal therapy for allergic bronchopulmonary aspergillosis. Chest. 103(1):299–301, 1993.PubMedCrossRefGoogle Scholar
  13. 13.
    Agarwal R., A. N. Agarwal, D. Gupta, S. K. Jindal. Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma : systematic review and meta-analysis. Int J Tuberc Lung Dis. 13:936, 2009.PubMedGoogle Scholar
  14. 14.
    Denning D.W., B. R. O’Driscoll, G. Powell et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med.179:11, 2009.Google Scholar
  15. 15.
    Reiff, D. B., A. U. Wells, D. H. Carr, P. J. Cole, and D. M. Hansell: CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. AJR Am J Roentgenol. 165(2):261–7, 1995.PubMedGoogle Scholar
  16. 16.
    Pasqualotto A.C., M. O. Xavier, L. B. Sanchez, C. D. de Oliveira Costa, S. M. Schio, S. M. Camargo, J. J. Camargo, T. C. Sukiennik, L. C. Severo. Diagnosis of invasive aspergillosis in lung transplant recipients by detection of galactomannan in the bronchoalveolar lavage fluid. Transplantation. 15; 90(3):306–11, 2010.Google Scholar
  17. 17.
    Senn L., J. O. Robinson, S. Schmidt S, et al. 1,3-β-d-Glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis. 46:878–85, 2008.Google Scholar
  18. 18.
    Ostrosky-Zeichner L., B. D Alexander, D. H. Kett, et al. Multicenter clinical evaluation of the (1®3) β-d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 41:654–9, 2005.Google Scholar
  19. 19.
    Saraceno, J. L., D. T. Phelps, T. J. Ferro, R. Futerfas, and D. B. Schwartz: Chronic necrotizing pulmonary aspergillosis: approach to management. Chest. 112(2):541–8, 1997.PubMedCrossRefGoogle Scholar
  20. 20.
    Safirstein, B. H., M. F. D’Souza, G. Simon, E. H. Tai, and J. Pepys: Five-year follow-up of allergic bronchopulmonary aspergillosis. Am Rev Respir Dis. 108(3):450–9, 1973.PubMedGoogle Scholar
  21. 21.
    Rosenberg, M., R. Mintzer, D. W. Aaronson, and R. Patterson: Allergic bronchopulmonary aspergillosis in three patients with normal chest x-ray films. Chest. 72(5):597–600, 1977.PubMedCrossRefGoogle Scholar
  22. 22.
    Skov M., C. Koch, C. M. Reimert, I. K. Poulsen, Diagnosis of allergic bronchopulmonary aspergillosis ABPA in cystic fibrosis. Allergy. 55(1):50–8, 2000.Google Scholar
  23. 23.
    Knutsen A.P., K. R. Mueller, P. S. Hutcheson, R. G. Slavin. Serum anti-Aspergillus fumigatus antibodies by immunoblot and ELISA in cystic fibrosis with allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 93(5):926–31, 1994.PubMedCrossRefGoogle Scholar
  24. 24.
    O’Driscoll B.R., G. Powell, F. Chew, R. M. Niven, J.F. Miles, A. Vyas, Denning DW. Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. Clin Exp Allergy, 39 (11):1677–83, 2009.Google Scholar
  25. 25.
    O’Driscoll, BR, G Powell, F. Chew, R.M.Niven, J.F. Miles, A. Vyas, D. W. Denning. Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. Clin Exp Allergy; 39(11):1677–83, 2009.Google Scholar
  26. 26.
    Latzin P., D. Hart, N. Regamey, U. Frey, M. H. Schoeni, C. Casaulta. Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis. Eur Respir J. 31(1):36–42, 2008.PubMedCrossRefGoogle Scholar
  27. 27.
    Kumar, R., and S. N. Gaur: Prevalence of allergic bronchopulmonary aspergillosis in patients with bronchial asthma. Asian Pac J Allergy Immunol. 18(4):181–5, 2000.PubMedGoogle Scholar
  28. 28.
    O’Connor, T. M., A. O’Donnell, M. Hurley, and C. P. Bredin: Allergic bronchopulmonary aspergillosis: a rare cause of pleural effusion. Respirology. 6(4):361–3, 2001.PubMedCrossRefGoogle Scholar
  29. 29.
    Panchal, N., R. Bhagat, C. Pant, and A. Shah: Allergic bronchopulmonary aspergillosis: the spectrum of computed tomography appearances. Respir Med. 91(4):213–9, 1997.PubMedCrossRefGoogle Scholar
  30. 30.
    Munro, N. C., L. Y. Han, D. C. Currie, B. Strickland, and P. J. Cole: Radiological evidence of progression of bronchiectasis. Respir Med. 86(5):397–401, 1992.PubMedCrossRefGoogle Scholar
  31. 31.
    Rosenberg, M., R. Patterson, and M. Roberts: Immunologic responses to therapy in allergic bronchopulmonary aspergillosis: serum IgE value as an indicator and predictor of disease activity. J Pediatr. 91(6):914–7, 1977.PubMedCrossRefGoogle Scholar
  32. 32.
    Pasqualotto A.C., G. Powell, R. Niven, D. W. Denning. The effects of antifungal therapy on severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis. Respirology. 14(8):1121–7, 2009.Google Scholar
  33. 33.
    Pasteur, M. C., S. M. Helliwell, S. J. Houghton, S. C. Webb, J. E. Foweraker, R. A. Coulden, C. D. Flower, D. Bilton, and M. T. Keogan: An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 162(4 Pt 1):1277–84, 2000.PubMedGoogle Scholar
  34. 34.
    Nepomuceno, I. B., S. Esrig, and R. B. Moss: Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole. Chest. 115(2):364–70, 1999.PubMedCrossRefGoogle Scholar
  35. 35.
    Patterson, R., P. A. Greenberger, R. C. Radin, and M. Roberts: Allergic bronchopulmonary aspergillosis: staging as an aid to management. Ann Intern Med. 96(3):286–91, 1982.PubMedGoogle Scholar
  36. 36.
    Kumar, R., P. Singh, R. Arora, and S. N. Gaur: Effect of itraconazole therapy in allergic bronchopulmonary aspergillosis. Saudi Med J. 24(5):546–7, 2003.PubMedGoogle Scholar
  37. 37.
    Kiely, J. L., L. Spense, M. Henry, M. F. Hurley, N. Kelleher, and C. P. Bredin: Chest radiographic staging in allergic bronchopulmonary aspergillosis: relationship with immunological findings. Eur Respir J. 12(2):453–6, 1998.PubMedCrossRefGoogle Scholar
  38. 38.
    Mroueh, S., and A. Spock: Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Chest. 105(1):32–6, 1994.PubMedCrossRefGoogle Scholar
  39. 39.
    Marchand, E., C. Verellen-Dumoulin, M. Mairesse, L. Delaunois, P. Brancaleone, J. F. Rahier, and O. Vandenplas: Frequency of cystic fibrosis transmembrane conductance regulator gene mutations and 5T allele in patients with allergic bronchopulmonary aspergillosis. Chest. 119(3):762–7, 2001.PubMedCrossRefGoogle Scholar
  40. 40.
    Cordier, J. Eosinophilic Pneumonias. In M. I. a. K. Schwarz, T. E., editor. Intersitial Lung Disease, 4th ed. B C Decker, Inc., Hamilton, Ontario. 657–700, 2003.Google Scholar
  41. 41.
    Stevens, D. A., H. J. Schwartz, J. Y. Lee, B. L. Moskovitz, D. C. Jerome, A. Catanzaro, D. M. Bamberger, A. J. Weinmann, C. U. Tuazon, M. A. Judson, T. A. Platts-Mills, and A. C. DeGraff, Jr.: A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med. 342(11):756–62, 2000.PubMedCrossRefGoogle Scholar
  42. 42.
    Wark, P. A., M. J. Hensley, N. Saltos, M. J. Boyle, R. C. Toneguzzi, G. D. Epid, J. L. Simpson, P. McElduff, and P. G. Gibson: Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol. 111(5):952–7, 2003.PubMedCrossRefGoogle Scholar
  43. 43.
    Murphy, M., E. M. Bernard, T. Ishimaru, and D. Armstrong: Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 41(3):696–8, 1997.PubMedGoogle Scholar
  44. 44.
    Fujimori, Y., S. Tada, M. Kataoka, M. Kawaraya, S. Ikubo, M. Horiba, M. Okahara, H. Takehara, M. Harada, and K. Tanabe: [Allergic bronchopulmonary aspergillosis effectively treated with itraconazole]. Nihon Kokyuki Gakkai Zasshi. 36(9):781–6, 1998.PubMedGoogle Scholar
  45. 45.
    Seaton, A., R. A. Seaton, and A. J. Wightman: Management of allergic bronchopulmonary aspergillosis without maintenance oral corticosteroids: a fifteen-year follow-up. Qjm. 87(9):529–37, 1994.PubMedGoogle Scholar
  46. 46.
    Inhaled beclomethasone dipropionate in allergic bronchopulmonary aspergillosis. Report to the Research Committee of the British Thoracic Association. Br J Dis Chest. 73(4):349–56, 1979.Google Scholar
  47. 47.
    Henderson, A. H., and J. E. Pearson: Treatment of bronchopulmonary aspergillosis with observations on the use of natamycin. Thorax. 23(5):519–23, 1968.PubMedCrossRefGoogle Scholar
  48. 48.
    Currie, D. C., C. Lueck, H. J. Milburn, C. Harvey, J. L. Longbottom, J. H. Darbyshire, A. J. Nunn, and P. J. Cole: Controlled trial of natamycin in the treatment of allergic bronchopulmonary aspergillosis. Thorax. 45(6):447–50, 1990.PubMedCrossRefGoogle Scholar
  49. 49.
    Salez, F., A. Brichet, S. Desurmont, J. M. Grosbois, B. Wallaert, and A. B. Tonnel: Effects of itraconazole therapy in allergic bronchopulmonary aspergillosis. Chest. 116(6):1665–8, 1999.PubMedCrossRefGoogle Scholar
  50. 50.
    Glackin L., G. Leen, B. Elnazir, P. Greally. Voriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. Ir Med J. 102:29, 2009.Google Scholar
  51. 51.
    Hilliard T., S. Edwards, R. Buchdahl et al. Voriconazole therapy in children with cystic fibrosis. J Cyst Fibrosis.4(4):213–4, 2005.Google Scholar
  52. 52.
  53. 53.
    Zirbes J. M., C. E. Milla. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol. 43:607, 2008.PubMedCrossRefGoogle Scholar
  54. 54.
    van der, Ent C. K., H. Hoekstra, G. T. Rijkers. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 62:276, 2007.Google Scholar
  55. 55.
    Kanu, A., K. Patel,. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr Pulmonol. 43:1249, 2008.PubMedCrossRefGoogle Scholar
  56. 56.
    Lebecque, P., A. Leonard, C. Pilette. Omalizumab for treatment of ABPA exacerbations in CF patients. Pediatr Pulmonol; 44:516, 2009.Google Scholar
  57. 57.
    Deepak, R, A. Goel, S. Joshi, S. Chauhan, V. Mishra. Experience with recombinant anti-IgE antibody therapy in patients with non-cystic fibrosis allergic bronchopulmonary aspergillosis. Chest 138:511A, 2010.Google Scholar
  58. 58.
    Morrissey, B. M., and S. J. Evans: Severe bronchiectasis. Clin Rev Allergy Immunol. 25(3):233–47, 2003.PubMedCrossRefGoogle Scholar
  59. 59.
    Sancho, J. M., J. M. Ribera, A. Rosell, C. Munoz, and E. Feliu: Unusual invasive bronchial aspergillosis in a patient with acute lymphoblastic leukemia. Haematologica. 82(6):701–2, 1997.PubMedGoogle Scholar
  60. 60.
    Mussaffi H., J. Rivlin, I. Shalit, M. Ephros, H. Blau. Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. Eur Respir J. Feb; 25(2):324–8, 2005.Google Scholar
  61. 61.
    Shah, P.L, S. Mawdsley, K. Nash, P. Cullinan P, P.J. Cole, R. Wilson. Determinants of chronic infection with Staphylococcus aureus in patients with bronchiectasis. Eur Respir J. 14(6):1340–4, 1999.Google Scholar
  62. 62.
    Pinson, P., and M. Van der Straeten: Fibrotic stage of allergic bronchopulmonary candidiasis. Chest. 100(2):565–7, 1991.Google Scholar
  63. 63.
    Saini, S. K., S. R. Boas, A. Jerath, M. Roberts, and P. A. Greenberger: Allergic bronchopulmonary mycosis to Fusarium vasinfectum in a child. Ann Allergy Asthma Immunol. 80(5):377–80, 1998.PubMedCrossRefGoogle Scholar
  64. 64.
    Backman, K. S., M. Roberts, and R. Patterson: Allergic bronchopulmonary mycosis caused by Fusarium vasinfectum. Am J Respir Crit Care Med. 152(4 Pt 1):1379–81, 1995.PubMedGoogle Scholar
  65. 65.
    Miller, M. A., P. A. Greenberger, R. Amerian, J. H. Toogood, G. A. Noskin, M. Roberts, and R. Patterson: Allergic bronchopulmonary mycosis caused by Pseudallescheria boydii. Am Rev Respir Dis. 148(3):810–2, 1993.PubMedGoogle Scholar
  66. 66.
    Cimon, B., J. Carrere, J. F. Vinatier, J. P. Chazalette, D. Chabasse, and J. P. Bouchara: Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis. 19(1):53–6, 2000.PubMedCrossRefGoogle Scholar
  67. 67.
    Travis W.D., K. J. Kwon-Chung, Kliener De et al. Unusual aspects of Allergic Bronchopulmonary Fungal diseases: report of two cases due to Curvularia organism and associated with allergic fungal sinusitis. Hum Pathol. 22:1240–48, 1991.Google Scholar
  68. 68.
    Mroueh S., A. Spoch. Allergic Bronchopulmonary disease caused by Curvularia in a child. Pediatr Pulmonol. 12:123–26, 1992.PubMedCrossRefGoogle Scholar
  69. 69.
    Lake F.R., R. I. Gidlon, J. H. Froudist et al. Allergic Bronchopulmonary fungal disease caused by Bipolaris and Curvularia. Aus NZ J Med. 21:871–74,1991.Google Scholar
  70. 70.
    Gaur S.N., Z. U. Khan, K. Gupta. Allergic Bronchopulmonary Mycosis due to Blastomyces dermatitidis: Diagnosis and 20 year’s follow up of a case. Indian J Allergy Asthma Immunol. 19(2):75–80, 2005.Google Scholar
  71. 71.
    Shale, D. J., J. A. Faux, and D. J. Lane: Trial of ketoconazole in non-invasive pulmonary aspergillosis. Thorax. 42(1):26–31, 1987.PubMedCrossRefGoogle Scholar
  72. 72.
    Rosenberg, M., R. Patterson, R. Mintzer, B. J. Cooper, M. Roberts, and K. E. Harris: Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med. 86(4):405–14, 1977.PubMedGoogle Scholar
  73. 73.
    Howard, A. J, A. C. Pasqualotto and D.W. Denning: Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis, Clin Microbiol Infec. 16:683–688, 2010.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Christian M. Sebat
    • 1
    • 2
  • Mark V. Avdalovic
    • 1
  • Brian M. Morrissey
    • 3
    • 2
  1. 1.Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal MedicineUniversity of California at Davis, Sacramento Medical CenterSacramentoUSA
  2. 2.VA Northern California Health Care SystemMatherUSA
  3. 3.Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal MedicineUniversity of California at Davis, School of MedicineSacramentoUSA

Personalised recommendations